Previous 10 | Next 10 |
One of the big advantages individual investors have over fund managers is that no one is looking over their shoulders for quick results. Individuals can invest for the long term; they can hold through volatility and watch their investments provide massive returns over decades. In this r...
What some thought could have been the start of a meme stock rally for MindMed ( NASDAQ: MNMD ) appears to have ended, just one day after it began. After closing up 36% on Thursday, the psychedelic drug treatment company is flat in Friday morning trading. In Thursda...
MindMed, which is up 71% in Thursday premarket trading, appears to be the latest beneficiary of the meme stock craze. The company, which is developing psychedelic drug treatments, closed up 10% Wednesday. A recent story in the Financial Times about US college s...
COMPASS Pathways is developing a psychedelic drug to treat many mental illnesses. The drug appears to be safe and effective for a wide range of mental health problems. If the drug gets authorized and approved, it will be the only available pharmacological treatment for millions an...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The incredible healing properties of psychedelics are being discovered with every passing day. Their potential is massive and can flip the script for those struggling with mental health disorders. Moreover, the market oppor...
Compass Pathways PLC (NASDAQ: CMPS) is a mental health care company that is focused on improving patient access to evidence-based innovation in mental health. The company’s stock, which trades as CMPS on the NASDAQ has been performing well, with many attributing this positive perfor...
The following slide deck was published by COMPASS Pathways plc in conjunction with their 2022 Q2 earnings call. For further details see: COMPASS Pathways plc 2022 Q2 - Results - Earnings Call Presentation
Image source: The Motley Fool. COMPASS Pathways plc (NASDAQ: CMPS) Q2 2022 Earnings Call Aug 04, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: COMPASS Pathways plc (CMPS) Q2 2022 Earnings Call Transcript
COMPASS Pathways plc (CMPS) Q2 2022 Earnings Conference Call August 4, 2022, 8:00 AM ET Company Participants Steven Schultz - Senior Vice President, Investor Relations George Goldsmith - Co-Founder and CEO Dr. Guy Goodwin - Chief Medical Officer Mike Falvey -...
Psychedelic drug company Compass Pathways plc (Nasdaq: CMPS) reported its financial results for the second quarter 2022 and gave an update on recent progress across its business. Compass delivered a net loss for the quarter of $21.0 million, or $0.50 loss per share (includ...
News, Short Squeeze, Breakout and More Instantly...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...
New research has determined that psilocybin may impact the brain. Psilocybin is the primary psychoactive compound found in hallucinogenic mushrooms. When ingested, it distorts an individual’s perception of time, among other changes. Researchers have observed that in animals, psilocyb...